✦ LIBER ✦

Bacteriological safety of multi-use vials for specific immunotherapy

✍ Scribed by Bodo Niggemann; Thomas Regnath; Frank Friedrichs; Martina Millner-Uhlemann

Book ID: 110895449
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 55 KB
Volume: 21
Category: Article
ISSN: 0905-6157
DOI: 10.1111/j.1399-3038.2009.00970.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The safety of multi-dose vials in allerg

The safety of multi-dose vials in allergy immunotherapy

✍ Sandra Y. Lin; P. Chase Lay; Larry F. Hughes; Richard Bass 📂 Article 📅 2008 🏛 SAGE Publications 🌐 English ⚖ 122 KB

Safety Implications of Different Adminis

Safety Implications of Different Administration Routes for Specific Immunotherapy

✍ Cox, L. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Use of Electronic Medical Record for All

Use of Electronic Medical Record for Allergen Immunotherapy to enhance patient safety

✍ Buddiga, P.; Baz, M.N.; Bashir, M.H. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 42 KB

Immunotherapy for malignant gliomas: emp

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells

✍ Steven De Vleeschouwer; Stefaan W. Van Gool; Frank Van Calenbergh 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 478 KB

Immunotherapy safety: a prospective mult

Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases

✍ C. Moreno; J. Cuesta-Herranz; L. Fernández-Távora; E. Alvarez-Cuesta; on behalf 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB

Detection of peptide-specific cytotoxic

Detection of peptide-specific cytotoxic T-lymphocyte precursors used for specific immunotherapy of pancreatic cancer

✍ Nobuaki Suzuki; Yoshiaki Maeda; Shoko Tanaka; Naoya Hida; Takashi Mine; Koutaro 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 143 KB

## Abstract The prognosis of pancreatic cancer is extremely poor with a 5‐year survival of approximately 3%. Thus, the development of new treatment modalities, including a specific immunotherapy, is required. Our study investigated whether cytotoxic T‐lymphocyte (CTL) precursors reacting to peptide